KNRLF yields 3703.70% · JNJ yields 2.13%● Live data
📍 KNRLF pulled ahead of the other in Year 1
Combined, KNRLF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KNRLF + JNJ for your $10,000?
Kontrol Technologies Corp., through its subsidiaries, provides energy management, emission compliance, and air quality solutions and services in Canada and the United States. It offers turn-key solutions to building owners and asset managers in the commercial, industrial, and multi-residential sector, which include software to analyze the management of heating, cooling, and ventilation (HVAC) systems; design and engineering of improvements and/or retrofits; and ongoing mission critical services. The company also provides integrated installations of heating, ventilation, cooling, and business automation systems to its customers; greenhouse gas verification, installation of critical emission management systems, and stack testing for environmental emissions; and Kontrol BioCloud, a solution to provide real-time viral detection technology. In addition, it offers energy auditing, monitoring and verification, energy project assessment, mechanical, electrical, and renewable design, as well as LEED facilitation services; monitoring, operation, and service of essential heating, cooling, ventilation, and utility systems; stack emission testing, continuous emission testing, power generation, due diligence, odour assessment and analytics, compliance, and other engineering services; and monitoring solutions, services, and product sales. The company is headquartered in Vaughan, Canada.
Full KNRLF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.